ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mibavademab

Also written as “Mibavademab”, “REGN4461” and “Low-Dose REGN4461”.

Its studies are mostly in Obesity, Morbid · Lipodystrophy, Familial Partial · Amenorrhea · Obesity, led by 2 companies.

Drug pageMibavademab: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 7, 20248 company-led studies, 3 open or runningNext primary completion: Jun 18, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticalsits history only73 open or runningphase 3since Aug 7, 2024May 7, 2018Jun 18, 2027phase 3 · NCT07220772
Eli Lilly10 open or runningphase 2since Apr 16, 2024Apr 16, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named mibavademabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, REGN4461
  2. Apr 16, 2024First study: phase 2 study in ObesityFirst studyNCT06373146 · 392 enrolled · United States

TargetBeta

LEPR →read by rule
“Leptin receptor agonist”ChEMBL 37, by rule

Studies

The one study Eli Lilly leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06373146Obesity · United States2CompletedDec 15, 2025392

How it is read

Names in the registry

  • “Mibavademab”, 4 entries
  • “REGN4461”, 2 entries
  • “mibavademab”, 1 entry
  • “Low-Dose REGN4461”, 1 entry
  • “High-dose REGN4461”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.